For decades, daily low-dose aspirin was hailed as a universal pill for healthy aging. But after landmark trials revealed that bleeding risks outweigh benefits in healthy older adults, guidelines pulled back the recommendation. Now, a study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association has reignited scientific debate: could low-dose aspirin significantly reduce dementia risk, but only for people with a specific genetic profile?
The research, led by Monash University, analyzed data from more than 13,500 participants in the landmark ASPREE clinical trial. Researchers found that individuals in the top 20% of a genetic score tied to platelet production experienced an estimated 70% lower relative hazard of developing dementia when assigned to daily low-dose aspirin compared to placebo. However, the exact same genetic subgroup experienced more than double the risk of major hemorrhages.
Before anyone considers reaching into the medicine cabinet for cognitive protection, medical researchers urge extreme caution. Here is an evidence-based look at what this new study discovered, why it does not change current clinical advice, and how precision pharmacogenomics is reshaping preventive medicine.
The Backstory: Why Broad Aspirin Recommendations Changed
To understand the new dementia findings, it helps to review why daily aspirin fell out of favor for primary prevention. In 2018, the New England Journal of Medicine published core ASPREE trial results, following more than 19,000 healthy older adults over nearly five years.
The trial evaluated whether 100 milligrams of daily enteric-coated aspirin prolonged life free of physical disability or dementia. The findings were decisive: aspirin did not prolong disability-free survival, nor did it lower overall rates of cognitive decline or cardiovascular events in healthy individuals. Crucially, it significantly increased major bleeding events, including intracranial hemorrhages and gastrointestinal bleeding.
Following ASPREE and complementary clinical trials, the U.S. Preventive Services Task Force (USPSTF) updated national recommendations, advising against initiating daily low-dose aspirin for primary prevention in adults aged 60 and older. Daily aspirin remains a cornerstone for secondary prevention—individuals who have already suffered a heart attack or stroke—under physician supervision, as emphasized by the American Heart Association.
The 2026 Discovery: Platelet Genetics and Cognitive Protection
Despite neutral results across general populations, researchers suspected that biological differences mask individual responses. In the new study, lead investigator Dr. Peter Fransquet and colleagues analyzed biobanked DNA from 13,541 ASPREE participants. The team screened 5,182 polygenic scores (PGSs) to evaluate whether specific genetic traits modified how participants responded to aspirin over an average follow-up of 4.7 years.
The investigators discovered a statistically significant interaction concentrated around platelets—cell fragments vital for blood clotting. Specifically, participants in the highest quintile (top 20%) of platelet-count polygenic scores (such as PGS003548) who took 100 mg of aspirin daily experienced a hazard ratio of 0.28 for incident dementia compared to placebo. This corresponds to an approximate 72% relative risk reduction in dementia diagnoses within that specific subgroup. Notably, this signal was independent of the APOE ε4 allele, the primary genetic risk factor for late-onset Alzheimer’s disease.
| Clinical Parameter | General ASPREE Cohort (Overall Trial) | High-Platelet PGS Subgroup (Top 20%) |
|---|---|---|
| Sample Size Analyzed | 19,114 older adults | ~2,708 genotyped participants |
| Aspirin Regimen | 100 mg enteric-coated daily vs. placebo | 100 mg enteric-coated daily vs. placebo |
| Dementia Hazard Ratio (HR) | HR 0.98 (No statistically significant benefit) | HR 0.28 (~72% relative risk reduction) |
| Major Bleeding Hazard Ratio | HR 1.38 (38% increase in major bleeding) | HR 2.13 (113% increase; 4.4% vs 2.1%) |
| Clinical Status | Standard guideline: Not recommended | Hypothesis-generating; not for clinical use |
The Critical Trade-Off: Bleeding Risks More Than Doubled
While a 70% relative risk reduction appears striking, the study uncovered a severe clinical counterweight. In the identical high-platelet genetic subgroup that saw cognitive protection, participants taking aspirin experienced a more than twofold increase in major bleeding events.
Major hemorrhages occurred in 4.4% of participants in the aspirin group compared to 2.1% in the placebo group (hazard ratio 2.13). These events encompass gastrointestinal hemorrhages and intracranial bleeding, both of which carry high mortality and long-term functional impairment in older adults.
From a public health perspective, this sharp elevation in bleeding risk offsets potential neuroprotective signals when applied broadly. Because hemorrhagic strokes directly cause brain injury, attempting to prevent cognitive decline with an agent that doubles major bleeding would harm far more individuals than it protects.
Biological Mechanisms: Platelets and the Aging Brain
Why would a genetic propensity for higher platelet counts influence dementia onset? Neuroscientists point to the relationship between microvascular health and neurodegeneration.
When activated, platelets release pro-inflammatory cytokines and chemokines. In individuals with genetically heightened platelet activity, chronic low-grade platelet aggregation within delicate cerebral microvessels may contribute to microvascular thrombosis, localized hypoxia, and breakdown of the blood-brain barrier.
According to the National Institute on Aging (NIA), vascular contributions to cognitive impairment and dementia (VCID) represent a widespread underlying driver of memory loss, frequently co-occurring with classic amyloid and tau pathologies. By blunting thromboxane A2 production, aspirin prevents platelet aggregation. In individuals genetically prone to microvascular clotting, aspirin might preserve capillary perfusion—though at the expense of systemic vascular fragility.
Study Limitations and Evidence Quality
Clinicians emphasize several critical study boundaries:
- Post-Hoc Subgroup Analysis: This was a retrospective, exploratory analysis of an existing trial dataset. Testing thousands of polygenic scores introduces statistical risks of multiple testing, meaning some associations could arise by chance.
- Association vs. Causation: While participants were originally randomized, genetic stratification was observational within that trial. Prospective trials stratifying participants by genetics prior to randomization are required to prove causality.
- Ancestry Constraints: Over 90% of genotyped participants were of white European descent. Because polygenic scores do not automatically transfer across diverse ancestries, these findings cannot be generalized broadly.
- No Clinical Diagnostic Exists: Polygenic risk scoring for platelet traits remains an academic research tool. No routine clinical test currently exists to identify potential responders.
The Road Ahead: Precision Medicine Replaces Blanket Rules
Rather than suggesting that older adults should resume daily aspirin, this landmark study represents an important proof of concept for precision medicine. The era of “one-size-fits-all” preventive pharmacology is shifting toward individualized care.
In the future, genomic profiling may allow clinicians to identify individuals whose microvascular profile justifies antiplatelet therapy while protecting others from dangerous hemorrhages. For now, established medical guidance remains clear: do not take daily aspirin on your own to prevent dementia.
Proven strategies for preserving cognitive health remain grounded in lifestyle interventions with established safety profiles: maintaining optimal blood pressure, engaging in regular physical exercise, prioritizing restorative sleep, adopting a nutrient-dense dietary pattern, and managing cardiometabolic markers under professional guidance.
Sources and Further Reading
- Fransquet, P. D., et al. (2026). Platelet count polygenic scores may modify the effect of aspirin in primary prevention of dementia. Alzheimer’s & Dementia. PubMed: 42781890
- McNeil, J. J., et al. (2018). Effect of Aspirin on Disability-free Survival in the Healthy Elderly (ASPREE). The New England Journal of Medicine. NEJM Article
- U.S. Preventive Services Task Force. (2022). Aspirin Use to Prevent Cardiovascular Disease: Recommendation Statement. JAMA. USPSTF Guidelines
- National Institute on Aging (NIA). (2026). Alzheimer’s Disease and Related Dementias: Overview and Vascular Risk Factors. National Institutes of Health (NIH)
- American Heart Association. (2024). Aspirin and Heart Disease: Clinical Guidance for Secondary Prevention. American Heart Association Guidelines
Related Reading
- Daily Aspirin: Who Should Still Take It in 2026
- Daily Aspirin: 7 Common Myths, Finally Debunked
- Intensive Blood Pressure Control Cuts Dementia Risk 15%
- Mini-Strokes and Dementia Risk: What a 20-Year Study Reveals
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.